Rimonabant (also known as SR141716, Acomplia, Riobant, Slimona, Rimoslim, and Zimulti) is an anorectic anti-obesity drug. It is a CB1 cannabinoid receptor antagonist. Its main avenue of effect is reduction in appetite.



Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. In Europe, it is indicated for use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m?, or patients wih a BMI greater than 27 kg/m? with associated risk factors, such as type 2 diabetes or dyslipidaemia. In the UK, it has been available since the end of July 2006. As of 2007, the drug was available in 38 countries.

Rimonabant Acomplia Benefits

Besides, weight loss Acomplia Rimonabant is also beneficial for smoking cessation and cardio-vascular/ metabolic related risk factors related to obesity. Acomplia Rimonabant's 2yrs clinical trials have reflected promising signs of averting weight regain after preceding weight loss.

Rimonabant Acomplia Dosage

The usual prescribed dosage of Acomplia (Rimonabant) is 20mg. Do not overdose it. Strictly adhere to your doctor's prescription for a desirable weight loss.

It is advisable to make your doctor well-informed regarding your medical history including any medication you may be engaged in. Pregnant women and nursing mothers should abstain from intake of Acomplia (Rimonabant).

Chantix / Champix Quit Smoking Drug

The most popular and effective treatment is the use of Chantix, the anti-smoking drug which was approved by the FDA on May 11, 2006. Chantix Champix is the only medicine which lives upto its reputation and name. Due to its effectiveness doctors today are prescribing chantix to most of their patient who come for anti-smoking treatment. Only if they are allergic or face severe side effects only then they are referred another treatment. One doctor says out of the 22 patients he had prescribed chantix, 18 of them have already quit smoking completely.

Buy Rimonabant for weight loss treatment

Rimonabant is an oral prescription drug, which acts as an appetite suppressant, for weight loss treaetment. Rimonabant does not only help for weight loss treatment but also for smoking cessation. But RImonabant is yet awaiting approval for smoking cessation treatment. Rimonabant was launched in June, 2006 after an agreement met by the 25-member European Union

Rimonabant workings - Buy Acomplia Online

Rimonabant functions on the principle of obstructing the CB-1 receptors, which are responsible for food and nicotine intake. This activity reduces your appetite and you tend to eat less than your normal appetite, leading to weight loss.

Approval report of EMEA (European Medicines Agency) is an authenticate source to find the side effects of Rimonabant. Rimonabant side effects can be enumerated as:

? Nausea

? Stomach upset

? Dizziness

? Vomiting

? Anxiety

? Irritability

Rimonabant Acomplia Dosage

The customary dosage of Acomplia (Rimonabant) is 20mg which is to be swallowed with a full glass of water. It should be consumed once in a day before breakfast. When accompanied with a controlled diet plan and regular workout, Rimonabant can show magical weight loss results. Prior discussion with a doctor is recommended before undertaking Rimonabant weight loss program.

Buy Acomplia in USA and Canada

Rimonabant is sold under brand name Zimulti in USA and Canada. Rimonabant is yet awaiting approval from FDA and is not yet approved as smoking cessation treatment. Rimonabant is just available for Weight loss or obesity treatment.

Side effects

Shortly after market introduction, press reports and independent studies suggest that side effects occur stronger and more commonly than shown by the manufacturer in their clinical studies. Reports of severe depression are frequent. This is deemed to result from the drug being active in the central nervous system, an area of human physiology so complex that drug effects are highly difficult to determine reliably.The reported development of previously clinically silent multiple sclerosis in one patient taking Rimonabant suggests that any patients with an underlying neurological condition should not take Rimonabant, given the neuroprotective role of the endocannabinoid system in many experimental paradigms of neurological disease.

On 15 June 2007 the BBC News reported that a committee advising the US FDA has voted not to recommend the drug's approval because of concerns over suicidality, depression and other related side effects associated with use of the drug.